QuartataWeb
Home  |   About  |   Theory  |   Tutorials  |   FAQ  |   Bahar Lab  |   Statistics
 

Network of interactions between drugs (red spheres) and targets (blue spheres) is displayed above.
The red lines are used for the predicted interactions and the thickness of edges indicate the confidence score of predictions.

Data source: DrugBank-all; Query type: target; # of requested predictions: 20; Secondary interactions: no
Input target 1: P08473
No. Gene UniProt ID Protein Name Pathway PDB
1 MME P08473 Neprilysin hsa04614; hsa04640; hsa04974; hsa05010 1DL9; 1DMT; 1QVD; 1R1H; 1R1I; 1R1J; 1Y8J; 2QPJ; 2YB9; 4CTH


11 known interactions (drugs) of input target (MME): Neprilysin
No. Group Type Drug ID Drug Name SMILES
⇨ TargetHunter		 Image
1 Experimental SmallMoleculeDrug DB02558 N-(3-Phenyl-2-Sulfanylpropanoyl)Phenylalanylalanine Thumb
2 Experimental SmallMoleculeDrug DB02597 [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala Thumb
3 Experimental SmallMoleculeDrug DB02557 Phosphoramidon Thumb
4 Investigational SmallMoleculeDrug DB05796 Daglutril Thumb
5 Experimental SmallMoleculeDrug DB08626 Thiorphan Thumb
6 Experimental SmallMoleculeDrug DB02062 N-[3-[(1-Aminoethyl)(Hydroxy)Phosphoryl]-2-(1,1'-Biphenyl-4-Ylmethyl)Propanoyl]Alanine Thumb
7 Experimental SmallMoleculeDrug DB00616 Candoxatril Thumb
8 Investigational SmallMoleculeDrug DB00886 Omapatrilat Thumb
9 Approved SmallMoleculeDrug DB09292 Sacubitril Thumb
10 Experimental SmallMoleculeDrug DB08575 2-[(1S)-1-BENZYL-2-SULFANYLETHYL]-1H-IMIDAZO[4,5-C]PYRIDIN-5-IUM Thumb
11 Experimental SmallMoleculeDrug DB11623 Candoxatrilat Thumb


20 predicted interactions (drugs) of input target (MME): Neprilysin
No. Group Type Drug ID Drug Name SMILES
⇨ TargetHunter		 Image Confidence score
1 Approved;
Nutraceutical;
Vet approved		 SmallMoleculeDrug DB00162 Vitamin A Thumb 29.7%
2 Approved;
Nutraceutical		 SmallMoleculeDrug DB00157 NADH Thumb 28.4%
3 Experimental SmallMoleculeDrug DB03680 Tartronate Thumb 27.4%
4 Approved;
Vet approved		 SmallMoleculeDrug DB00945 Acetylsalicylic acid Thumb 27.0%
5 Experimental SmallMoleculeDrug DB08235 N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide Thumb 23.9%
6 Approved;
Investigational		 SmallMoleculeDrug DB01103 Quinacrine Thumb 22.9%
7 Experimental SmallMoleculeDrug DB08231 Myristic acid Thumb 21.5%
8 Approved;
Investigational;
Withdrawn		 BiotechDrug DB00055 Drotrecogin alfa Thumb 21.0%
9 Experimental SmallMoleculeDrug DB07340 N~6~-cyclohexyl-N~2~-(4-morpholin-4-ylphenyl)-9H-purine-2,6-diamine Thumb 21.0%
10 Approved;
Nutraceutical;
Vet approved		 SmallMoleculeDrug DB14002 D-alpha-Tocopherol acetate Thumb 20.8%
11 Experimental SmallMoleculeDrug DB02506 2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid Thumb 20.6%
12 Approved SmallMoleculeDrug DB00480 Lenalidomide Thumb 20.3%
13 Approved SmallMoleculeDrug DB00975 Dipyridamole Thumb 20.2%
14 Approved;
Experimental;
Investigational		 SmallMoleculeDrug DB02772 Sucrose Thumb 20.1%
15 Approved;
Investigational		 SmallMoleculeDrug DB01586 Ursodeoxycholic acid Thumb 19.4%
16 Experimental SmallMoleculeDrug DB04395 Phosphoaminophosphonic Acid-Adenylate Ester Thumb 18.6%
17 Experimental SmallMoleculeDrug DB07841 Geranylgeranyl diphosphate Thumb 18.6%
18 Investigational BiotechDrug DB04985 Tigapotide Thumb 18.5%
19 Approved;
Illicit		 SmallMoleculeDrug DB00470 Dronabinol Thumb 18.2%
20 Experimental SmallMoleculeDrug DB08220 (8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid Thumb 18.1%


  logl

Reference:  Hongchun Li, Fen Pei, D. Lansing Taylor and Ivet Bahar. (2020) QuartataWeb: Integrated Chemical–Protein-Pathway Mapping for Polypharmacology and Chemogenomics. Bioinformatics 36(12), 3935–3937.

Contact:

The QuartataWeb server is maintained by the Bahar Lab at the Department of Computational & Systems Biology at the University of Pittsburgh, School of Medicine, and sponsored by the NIH awards P41 GM103712 and P01 DK096990; and by the Li Lab at Research Center for Computer-Aided Drug Discovery at Shenzhen Institutes of Advanced Technology, CAS.

For questions and comments please contact Hongchun Li.